ORYZON to give updates on corporate progress in June

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in June.

Oryzon will participate at the Jefferies Healthcare 2022 conference, which will be held on June 8-10 in New York (USA). The company will provide a corporate update on June 10 at 12:45 pm EST and will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the Jefferies Healthcare conference

Oryzon’s medical team will attend the European Hematology Association congress, EHA-2022, which will be held on June 9-12 in Vienna (Austria) and virtually. The company will present an update on iadademstat’s ongoing Phase II ALICE trial in combination with azacitidine in acute myeloid leukemia (AML), with a poster communication entitled “Iadademstat combination with azacitidine shows encouraging safety and efficacy data in elderly and unfit AML patients”, to be presented on June 10 at 16:30 CET. Click on link for more info about EHA-2022

Oryzon will attend the BIO International Convention in San Diego (USA) on June 13-16, where the company will hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about the BIO International Convention

Oryzon will also attend the LSX World Congress, which will be held in Boston (USA) on June 21-22, where the company will hold meetings with pharmaceutical companies and global investors. Click on link for more info about the LSX World Congress